Paul L. Berns - May 28, 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Title: Chief Executive Officer and Chairman of the Board, Director
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns
Stock symbol
NMRA
Transactions as of
May 28, 2025
Transactions value $
$0
Form type
4
Date filed
5/30/2025, 06:30 PM
Previous filing
May 22, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BERNS PAUL L Title: Chief Executive Officer and Chairman of the Board, Director C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns 2025-05-30 0001202769

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -497K -100% 0 May 28, 2025 Common Stock 497K $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -956K -100% 0 May 28, 2025 Common Stock 956K $1.69 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -343K -100% 0 May 28, 2025 Common Stock 343K $1.69 Direct F2, F4
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -2M -100% 0 May 28, 2025 Common Stock 2M $1.69 Direct F2, F5
transaction NMRA Stock Option (Right to Buy) Award +497K 497K May 28, 2025 Common Stock 497K $0.72 Direct F1, F2, F6
transaction NMRA Stock Option (Right to Buy) Award +956K 956K May 28, 2025 Common Stock 956K $0.72 Direct F2, F3, F6
transaction NMRA Stock Option (Right to Buy) Award +343K 343K May 28, 2025 Common Stock 343K $0.72 Direct F2, F4, F6
transaction NMRA Stock Option (Right to Buy) Award +2M 2M May 28, 2025 Common Stock 2M $0.72 Direct F2, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged.
F3 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F5 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F6 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Remarks:

Title: Chief Executive Officer and Chairman of the Board